Categories
Life Sciences Consumer Goods Materials and Chemicals Construction & Manufacturing Food and Beverages Energy and Power Semiconductor and Electronics Automotive and Transportation ICT & Media Aerospace & Defense BFSI

Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com

Aphakia Market by Type (Congenital aphakia, Surgical aphakia, Acquired aphakia), by Treatment (Spectacles, Contact lenses, Intraocular lens Implantation, Refractive surgery) and by End User (Hospitals, Ophthalmic clinics, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032

A12313

Pages: NA

Charts: NA

Tables: NA

Aphakia Market Statistics 2030:

Aphakia is a condition in which crystalline lens of the eye is not present in its normal position of papillary area. Either there is no lens inside the eye or the lens is subluxated/dislocated. This condition is most common in adults with cataract, but it can also affect infants and children. Options available to correct aphakia are glasses, contact lens, kerato refractive surgery, and intraocular lens (IOL). Replacement of the crystalline lens with a spectacle lens causes the image on patient’s retina to be roughly 25% larger than the image formed with the crystalline lens. The exact magnification is determined by the power of the aphakic spectacles.

COVID-19 scenario analysis

The pandemic has led to an unprecedented burden on the healthcare system, providers, patients, and the general public. The virus and its subsequent impact have not, however, affected all individuals equally. Specifically, racial and ethnic minorities and those individuals with comorbidities have been disproportionately affected by COVID-19. The National Blindness and Visually Impaired Survey 2019 claims that the most number of cases of blindness in India happen due to preventable causes. This means the rate of diagnosis is the major issue here. Blindness (92.9%) and visual impairment (96.2%) can be well prevented only if diagnosis and treatment are carried out on time. With the ongoing pandemic and previous lockdown, the lag of 3-4 months of not visiting a doctor for eye issues has certainly added to the burden of the blind population.

Top impacting factors: market scenario analysis, trends, drivers, and impact analysis

Increase in prevalence of eye diseases is expected to drive the demand for diagnostic and monitoring equipment in the ophthalmic devices industry. Rise in surgeries associated with eye disorders has increased the growth of the diagnostic and monitoring ophthalmic market. According to the National Institute of Health (NIH), by 2050, the number of people in the U.S. with cataract is expected to double from 24.4 million to about 50 million. Majority of cases will affect white people; however, Hispanic Americans are expected to have the most rapid increase in prevalence from 1.76 million cases to 9.51 million. Furthermore, surge in prevalence of diabetes & other diseases is the crucial aspect of rise in the market revenue of aphakia as well as increase in demand for better treatment will foster market growth. According to the Centers for Disease Control National Diabetes Statistics Report for 2020, cases of diabetes have risen to an estimated 34.2 million. According to the Centers for Disease Control and Prevention Trusted Source, about 32.2% percent of adults age 45 and over living with diabetes have cataracts. However, lack of awareness of eye disorders in developing and underdeveloped countries is expected to hinder the growth of the aphakia market.

Key benefits of the report

  • This study presents the analytical depiction of the global aphakia market along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the aphakia market share.
  • The current market is quantitatively analyzed to highlight the global aphakia market growth scenario.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
  • The report provides a detailed aphakia market analysis depending on competitive intensity and how the competition will take shape in coming years.

Questions answered in the aphakia market research report

  • Which are the leading players active in the aphakia market?
  • What are the current trends that will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities of the market?
  • What are the projections for the future that would help in taking further strategic steps?

Key Market Segments

  • By Type
    • Congenital aphakia
    • Surgical aphakia
    • Acquired aphakia
  • By Treatment
    • Spectacles
    • Contact lenses
    • Intraocular lens Implantation
    • Refractive surgery
  • By End User
    • Hospitals
    • Ophthalmic clinics
    • Others
  • By Region
    • North America
      • U.S.
      • Canada
      • Mexico
    • Europe
      • France
      • Germany
      • Italy
      • Spain
      • UK
      • Rest of Europe
    • Asia-Pacific
      • China
      • Japan
      • India
      • South Korea
      • Australia
      • Rest of Asia-Pacific
    • LAMEA
      • Brazil
      • South Africa
      • Saudi Arabia
      • Rest of LAMEA


Key Market Players

  • Ophtec BV
  • Rayner Company
  • Johnson and Johnson
  • Carl Zeiss AG
  • Alcon Laboratories, Inc.
  • Aetna Inc.
  • Lifecore Biomedical, LLC
  • Bausch and Lomb
  • Bohus BioTech AB
  • CooperVision, Inc.
  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

  • CHAPTER 4: APHAKIA MARKET, BY TYPE

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Type

    • 4.2. Congenital Aphakia

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Surgical Aphakia

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Acquired Aphakia

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

  • CHAPTER 5: APHAKIA MARKET, BY TREATMENT

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Treatment

    • 5.2. Spectacles

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Contact Lenses

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Intraocular Lens Implantation

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

    • 5.5. Refractive Surgery

      • 5.5.1. Key Market Trends, Growth Factors and Opportunities

      • 5.5.2. Market Size and Forecast, By Region

      • 5.5.3. Market Share Analysis, By Country

  • CHAPTER 6: APHAKIA MARKET, BY END USER

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By End User

    • 6.2. Hospitals

      • 6.2.1. Key Market Trends, Growth Factors and Opportunities

      • 6.2.2. Market Size and Forecast, By Region

      • 6.2.3. Market Share Analysis, By Country

    • 6.3. Ophthalmic Clinics

      • 6.3.1. Key Market Trends, Growth Factors and Opportunities

      • 6.3.2. Market Size and Forecast, By Region

      • 6.3.3. Market Share Analysis, By Country

    • 6.4. Others

      • 6.4.1. Key Market Trends, Growth Factors and Opportunities

      • 6.4.2. Market Size and Forecast, By Region

      • 6.4.3. Market Share Analysis, By Country

  • CHAPTER 7: APHAKIA MARKET, BY REGION

    • 7.1. Market Overview

      • 7.1.1 Market Size and Forecast, By Region

    • 7.2. North America

      • 7.2.1. Key Market Trends and Opportunities

      • 7.2.2. Market Size and Forecast, By Type

      • 7.2.3. Market Size and Forecast, By Treatment

      • 7.2.4. Market Size and Forecast, By End User

      • 7.2.5. Market Size and Forecast, By Country

      • 7.2.6. U.S. Aphakia Market

        • 7.2.6.1. Market Size and Forecast, By Type
        • 7.2.6.2. Market Size and Forecast, By Treatment
        • 7.2.6.3. Market Size and Forecast, By End User
      • 7.2.7. Canada Aphakia Market

        • 7.2.7.1. Market Size and Forecast, By Type
        • 7.2.7.2. Market Size and Forecast, By Treatment
        • 7.2.7.3. Market Size and Forecast, By End User
      • 7.2.8. Mexico Aphakia Market

        • 7.2.8.1. Market Size and Forecast, By Type
        • 7.2.8.2. Market Size and Forecast, By Treatment
        • 7.2.8.3. Market Size and Forecast, By End User
    • 7.3. Europe

      • 7.3.1. Key Market Trends and Opportunities

      • 7.3.2. Market Size and Forecast, By Type

      • 7.3.3. Market Size and Forecast, By Treatment

      • 7.3.4. Market Size and Forecast, By End User

      • 7.3.5. Market Size and Forecast, By Country

      • 7.3.6. France Aphakia Market

        • 7.3.6.1. Market Size and Forecast, By Type
        • 7.3.6.2. Market Size and Forecast, By Treatment
        • 7.3.6.3. Market Size and Forecast, By End User
      • 7.3.7. Germany Aphakia Market

        • 7.3.7.1. Market Size and Forecast, By Type
        • 7.3.7.2. Market Size and Forecast, By Treatment
        • 7.3.7.3. Market Size and Forecast, By End User
      • 7.3.8. Italy Aphakia Market

        • 7.3.8.1. Market Size and Forecast, By Type
        • 7.3.8.2. Market Size and Forecast, By Treatment
        • 7.3.8.3. Market Size and Forecast, By End User
      • 7.3.9. Spain Aphakia Market

        • 7.3.9.1. Market Size and Forecast, By Type
        • 7.3.9.2. Market Size and Forecast, By Treatment
        • 7.3.9.3. Market Size and Forecast, By End User
      • 7.3.10. UK Aphakia Market

        • 7.3.10.1. Market Size and Forecast, By Type
        • 7.3.10.2. Market Size and Forecast, By Treatment
        • 7.3.10.3. Market Size and Forecast, By End User
      • 7.3.11. Russia Aphakia Market

        • 7.3.11.1. Market Size and Forecast, By Type
        • 7.3.11.2. Market Size and Forecast, By Treatment
        • 7.3.11.3. Market Size and Forecast, By End User
      • 7.3.12. Rest Of Europe Aphakia Market

        • 7.3.12.1. Market Size and Forecast, By Type
        • 7.3.12.2. Market Size and Forecast, By Treatment
        • 7.3.12.3. Market Size and Forecast, By End User
    • 7.4. Asia-Pacific

      • 7.4.1. Key Market Trends and Opportunities

      • 7.4.2. Market Size and Forecast, By Type

      • 7.4.3. Market Size and Forecast, By Treatment

      • 7.4.4. Market Size and Forecast, By End User

      • 7.4.5. Market Size and Forecast, By Country

      • 7.4.6. China Aphakia Market

        • 7.4.6.1. Market Size and Forecast, By Type
        • 7.4.6.2. Market Size and Forecast, By Treatment
        • 7.4.6.3. Market Size and Forecast, By End User
      • 7.4.7. Japan Aphakia Market

        • 7.4.7.1. Market Size and Forecast, By Type
        • 7.4.7.2. Market Size and Forecast, By Treatment
        • 7.4.7.3. Market Size and Forecast, By End User
      • 7.4.8. India Aphakia Market

        • 7.4.8.1. Market Size and Forecast, By Type
        • 7.4.8.2. Market Size and Forecast, By Treatment
        • 7.4.8.3. Market Size and Forecast, By End User
      • 7.4.9. South Korea Aphakia Market

        • 7.4.9.1. Market Size and Forecast, By Type
        • 7.4.9.2. Market Size and Forecast, By Treatment
        • 7.4.9.3. Market Size and Forecast, By End User
      • 7.4.10. Australia Aphakia Market

        • 7.4.10.1. Market Size and Forecast, By Type
        • 7.4.10.2. Market Size and Forecast, By Treatment
        • 7.4.10.3. Market Size and Forecast, By End User
      • 7.4.11. Thailand Aphakia Market

        • 7.4.11.1. Market Size and Forecast, By Type
        • 7.4.11.2. Market Size and Forecast, By Treatment
        • 7.4.11.3. Market Size and Forecast, By End User
      • 7.4.12. Malaysia Aphakia Market

        • 7.4.12.1. Market Size and Forecast, By Type
        • 7.4.12.2. Market Size and Forecast, By Treatment
        • 7.4.12.3. Market Size and Forecast, By End User
      • 7.4.13. Indonesia Aphakia Market

        • 7.4.13.1. Market Size and Forecast, By Type
        • 7.4.13.2. Market Size and Forecast, By Treatment
        • 7.4.13.3. Market Size and Forecast, By End User
      • 7.4.14. Rest of Asia Pacific Aphakia Market

        • 7.4.14.1. Market Size and Forecast, By Type
        • 7.4.14.2. Market Size and Forecast, By Treatment
        • 7.4.14.3. Market Size and Forecast, By End User
    • 7.5. LAMEA

      • 7.5.1. Key Market Trends and Opportunities

      • 7.5.2. Market Size and Forecast, By Type

      • 7.5.3. Market Size and Forecast, By Treatment

      • 7.5.4. Market Size and Forecast, By End User

      • 7.5.5. Market Size and Forecast, By Country

      • 7.5.6. Brazil Aphakia Market

        • 7.5.6.1. Market Size and Forecast, By Type
        • 7.5.6.2. Market Size and Forecast, By Treatment
        • 7.5.6.3. Market Size and Forecast, By End User
      • 7.5.7. South Africa Aphakia Market

        • 7.5.7.1. Market Size and Forecast, By Type
        • 7.5.7.2. Market Size and Forecast, By Treatment
        • 7.5.7.3. Market Size and Forecast, By End User
      • 7.5.8. Saudi Arabia Aphakia Market

        • 7.5.8.1. Market Size and Forecast, By Type
        • 7.5.8.2. Market Size and Forecast, By Treatment
        • 7.5.8.3. Market Size and Forecast, By End User
      • 7.5.9. UAE Aphakia Market

        • 7.5.9.1. Market Size and Forecast, By Type
        • 7.5.9.2. Market Size and Forecast, By Treatment
        • 7.5.9.3. Market Size and Forecast, By End User
      • 7.5.10. Argentina Aphakia Market

        • 7.5.10.1. Market Size and Forecast, By Type
        • 7.5.10.2. Market Size and Forecast, By Treatment
        • 7.5.10.3. Market Size and Forecast, By End User
      • 7.5.11. Rest of LAMEA Aphakia Market

        • 7.5.11.1. Market Size and Forecast, By Type
        • 7.5.11.2. Market Size and Forecast, By Treatment
        • 7.5.11.3. Market Size and Forecast, By End User
  • CHAPTER 8: COMPETITIVE LANDSCAPE

    • 8.1. Introduction

    • 8.2. Top Winning Strategies

    • 8.3. Product Mapping Of Top 10 Player

    • 8.4. Competitive Dashboard

    • 8.5. Competitive Heatmap

    • 8.6. Top Player Positioning, 2024

  • CHAPTER 9: COMPANY PROFILES

    • 9.1. Johnson And Johnson

      • 9.1.1. Company Overview

      • 9.1.2. Key Executives

      • 9.1.3. Company Snapshot

      • 9.1.4. Operating Business Segments

      • 9.1.5. Product Portfolio

      • 9.1.6. Business Performance

      • 9.1.7. Key Strategic Moves and Developments

    • 9.2. Ophtec BV

      • 9.2.1. Company Overview

      • 9.2.2. Key Executives

      • 9.2.3. Company Snapshot

      • 9.2.4. Operating Business Segments

      • 9.2.5. Product Portfolio

      • 9.2.6. Business Performance

      • 9.2.7. Key Strategic Moves and Developments

    • 9.3. Alcon Laboratories, Inc.

      • 9.3.1. Company Overview

      • 9.3.2. Key Executives

      • 9.3.3. Company Snapshot

      • 9.3.4. Operating Business Segments

      • 9.3.5. Product Portfolio

      • 9.3.6. Business Performance

      • 9.3.7. Key Strategic Moves and Developments

    • 9.4. Bausch And Lomb

      • 9.4.1. Company Overview

      • 9.4.2. Key Executives

      • 9.4.3. Company Snapshot

      • 9.4.4. Operating Business Segments

      • 9.4.5. Product Portfolio

      • 9.4.6. Business Performance

      • 9.4.7. Key Strategic Moves and Developments

    • 9.5. Carl Zeiss AG

      • 9.5.1. Company Overview

      • 9.5.2. Key Executives

      • 9.5.3. Company Snapshot

      • 9.5.4. Operating Business Segments

      • 9.5.5. Product Portfolio

      • 9.5.6. Business Performance

      • 9.5.7. Key Strategic Moves and Developments

    • 9.6. Rayner Company

      • 9.6.1. Company Overview

      • 9.6.2. Key Executives

      • 9.6.3. Company Snapshot

      • 9.6.4. Operating Business Segments

      • 9.6.5. Product Portfolio

      • 9.6.6. Business Performance

      • 9.6.7. Key Strategic Moves and Developments

    • 9.7. Bohus BioTech AB

      • 9.7.1. Company Overview

      • 9.7.2. Key Executives

      • 9.7.3. Company Snapshot

      • 9.7.4. Operating Business Segments

      • 9.7.5. Product Portfolio

      • 9.7.6. Business Performance

      • 9.7.7. Key Strategic Moves and Developments

    • 9.8. CooperVision, Inc.

      • 9.8.1. Company Overview

      • 9.8.2. Key Executives

      • 9.8.3. Company Snapshot

      • 9.8.4. Operating Business Segments

      • 9.8.5. Product Portfolio

      • 9.8.6. Business Performance

      • 9.8.7. Key Strategic Moves and Developments

    • 9.9. Lifecore Biomedical, LLC

      • 9.9.1. Company Overview

      • 9.9.2. Key Executives

      • 9.9.3. Company Snapshot

      • 9.9.4. Operating Business Segments

      • 9.9.5. Product Portfolio

      • 9.9.6. Business Performance

      • 9.9.7. Key Strategic Moves and Developments

    • 9.10. Aetna Inc.

      • 9.10.1. Company Overview

      • 9.10.2. Key Executives

      • 9.10.3. Company Snapshot

      • 9.10.4. Operating Business Segments

      • 9.10.5. Product Portfolio

      • 9.10.6. Business Performance

      • 9.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL APHAKIA MARKET, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 2. GLOBAL APHAKIA MARKET FOR CONGENITAL APHAKIA, BY REGION, 2025-2033 ($MILLION)
  • TABLE 3. GLOBAL APHAKIA MARKET FOR SURGICAL APHAKIA, BY REGION, 2025-2033 ($MILLION)
  • TABLE 4. GLOBAL APHAKIA MARKET FOR ACQUIRED APHAKIA, BY REGION, 2025-2033 ($MILLION)
  • TABLE 5. GLOBAL APHAKIA MARKET, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 6. GLOBAL APHAKIA MARKET FOR SPECTACLES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 7. GLOBAL APHAKIA MARKET FOR CONTACT LENSES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 8. GLOBAL APHAKIA MARKET FOR INTRAOCULAR LENS IMPLANTATION, BY REGION, 2025-2033 ($MILLION)
  • TABLE 9. GLOBAL APHAKIA MARKET FOR REFRACTIVE SURGERY, BY REGION, 2025-2033 ($MILLION)
  • TABLE 10. GLOBAL APHAKIA MARKET, BY END USER, 2025-2033 ($MILLION)
  • TABLE 11. GLOBAL APHAKIA MARKET FOR HOSPITALS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 12. GLOBAL APHAKIA MARKET FOR OPHTHALMIC CLINICS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 13. GLOBAL APHAKIA MARKET FOR OTHERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 14. GLOBAL APHAKIA MARKET, BY REGION, 2025-2033 ($MILLION)
  • TABLE 15. NORTH AMERICA APHAKIA, BY REGION, 2025-2033 ($MILLION)
  • TABLE 16. NORTH AMERICA APHAKIA, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 17. NORTH AMERICA APHAKIA, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 18. NORTH AMERICA APHAKIA, BY END USER, 2025-2033 ($MILLION)
  • TABLE 19. U.S. APHAKIA, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 20. U.S. APHAKIA, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 21. U.S. APHAKIA, BY END USER, 2025-2033 ($MILLION)
  • TABLE 22. CANADA APHAKIA, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 23. CANADA APHAKIA, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 24. CANADA APHAKIA, BY END USER, 2025-2033 ($MILLION)
  • TABLE 25. MEXICO APHAKIA, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 26. MEXICO APHAKIA, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 27. MEXICO APHAKIA, BY END USER, 2025-2033 ($MILLION)
  • TABLE 28. EUROPE APHAKIA, BY REGION, 2025-2033 ($MILLION)
  • TABLE 29. EUROPE APHAKIA, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 30. EUROPE APHAKIA, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 31. EUROPE APHAKIA, BY END USER, 2025-2033 ($MILLION)
  • TABLE 32. FRANCE APHAKIA, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 33. FRANCE APHAKIA, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 34. FRANCE APHAKIA, BY END USER, 2025-2033 ($MILLION)
  • TABLE 35. GERMANY APHAKIA, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 36. GERMANY APHAKIA, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 37. GERMANY APHAKIA, BY END USER, 2025-2033 ($MILLION)
  • TABLE 38. ITALY APHAKIA, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 39. ITALY APHAKIA, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 40. ITALY APHAKIA, BY END USER, 2025-2033 ($MILLION)
  • TABLE 41. SPAIN APHAKIA, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 42. SPAIN APHAKIA, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 43. SPAIN APHAKIA, BY END USER, 2025-2033 ($MILLION)
  • TABLE 44. UK APHAKIA, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 45. UK APHAKIA, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 46. UK APHAKIA, BY END USER, 2025-2033 ($MILLION)
  • TABLE 47. RUSSIA APHAKIA, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 48. RUSSIA APHAKIA, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 49. RUSSIA APHAKIA, BY END USER, 2025-2033 ($MILLION)
  • TABLE 50. REST OF EUROPE APHAKIA, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 51. REST OF EUROPE APHAKIA, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 52. REST OF EUROPE APHAKIA, BY END USER, 2025-2033 ($MILLION)
  • TABLE 53. ASIA-PACIFIC APHAKIA, BY REGION, 2025-2033 ($MILLION)
  • TABLE 54. ASIA-PACIFIC APHAKIA, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 55. ASIA-PACIFIC APHAKIA, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 56. ASIA-PACIFIC APHAKIA, BY END USER, 2025-2033 ($MILLION)
  • TABLE 57. CHINA APHAKIA, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 58. CHINA APHAKIA, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 59. CHINA APHAKIA, BY END USER, 2025-2033 ($MILLION)
  • TABLE 60. JAPAN APHAKIA, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 61. JAPAN APHAKIA, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 62. JAPAN APHAKIA, BY END USER, 2025-2033 ($MILLION)
  • TABLE 63. INDIA APHAKIA, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 64. INDIA APHAKIA, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 65. INDIA APHAKIA, BY END USER, 2025-2033 ($MILLION)
  • TABLE 66. SOUTH KOREA APHAKIA, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 67. SOUTH KOREA APHAKIA, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 68. SOUTH KOREA APHAKIA, BY END USER, 2025-2033 ($MILLION)
  • TABLE 69. AUSTRALIA APHAKIA, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 70. AUSTRALIA APHAKIA, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 71. AUSTRALIA APHAKIA, BY END USER, 2025-2033 ($MILLION)
  • TABLE 72. THAILAND APHAKIA, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 73. THAILAND APHAKIA, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 74. THAILAND APHAKIA, BY END USER, 2025-2033 ($MILLION)
  • TABLE 75. MALAYSIA APHAKIA, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 76. MALAYSIA APHAKIA, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 77. MALAYSIA APHAKIA, BY END USER, 2025-2033 ($MILLION)
  • TABLE 78. INDONESIA APHAKIA, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 79. INDONESIA APHAKIA, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 80. INDONESIA APHAKIA, BY END USER, 2025-2033 ($MILLION)
  • TABLE 81. REST OF ASIA PACIFIC APHAKIA, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 82. REST OF ASIA PACIFIC APHAKIA, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 83. REST OF ASIA PACIFIC APHAKIA, BY END USER, 2025-2033 ($MILLION)
  • TABLE 84. LAMEA APHAKIA, BY REGION, 2025-2033 ($MILLION)
  • TABLE 85. LAMEA APHAKIA, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 86. LAMEA APHAKIA, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 87. LAMEA APHAKIA, BY END USER, 2025-2033 ($MILLION)
  • TABLE 88. BRAZIL APHAKIA, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 89. BRAZIL APHAKIA, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 90. BRAZIL APHAKIA, BY END USER, 2025-2033 ($MILLION)
  • TABLE 91. SOUTH AFRICA APHAKIA, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 92. SOUTH AFRICA APHAKIA, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 93. SOUTH AFRICA APHAKIA, BY END USER, 2025-2033 ($MILLION)
  • TABLE 94. SAUDI ARABIA APHAKIA, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 95. SAUDI ARABIA APHAKIA, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 96. SAUDI ARABIA APHAKIA, BY END USER, 2025-2033 ($MILLION)
  • TABLE 97. UAE APHAKIA, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 98. UAE APHAKIA, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 99. UAE APHAKIA, BY END USER, 2025-2033 ($MILLION)
  • TABLE 100. ARGENTINA APHAKIA, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 101. ARGENTINA APHAKIA, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 102. ARGENTINA APHAKIA, BY END USER, 2025-2033 ($MILLION)
  • TABLE 103. REST OF LAMEA APHAKIA, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 104. REST OF LAMEA APHAKIA, BY TREATMENT, 2025-2033 ($MILLION)
  • TABLE 105. REST OF LAMEA APHAKIA, BY END USER, 2025-2033 ($MILLION)
  • TABLE 106. JOHNSON AND JOHNSON: KEY EXECUTIVES
  • TABLE 107. JOHNSON AND JOHNSON: COMPANY SNAPSHOT
  • TABLE 108. JOHNSON AND JOHNSON: OPERATING SEGMENTS
  • TABLE 109. JOHNSON AND JOHNSON: PRODUCT PORTFOLIO
  • TABLE 110. JOHNSON AND JOHNSON: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 111. OPHTEC BV: KEY EXECUTIVES
  • TABLE 112. OPHTEC BV: COMPANY SNAPSHOT
  • TABLE 113. OPHTEC BV: OPERATING SEGMENTS
  • TABLE 114. OPHTEC BV: PRODUCT PORTFOLIO
  • TABLE 115. OPHTEC BV: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 116. ALCON LABORATORIES, INC.: KEY EXECUTIVES
  • TABLE 117. ALCON LABORATORIES, INC.: COMPANY SNAPSHOT
  • TABLE 118. ALCON LABORATORIES, INC.: OPERATING SEGMENTS
  • TABLE 119. ALCON LABORATORIES, INC.: PRODUCT PORTFOLIO
  • TABLE 120. ALCON LABORATORIES, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 121. BAUSCH AND LOMB: KEY EXECUTIVES
  • TABLE 122. BAUSCH AND LOMB: COMPANY SNAPSHOT
  • TABLE 123. BAUSCH AND LOMB: OPERATING SEGMENTS
  • TABLE 124. BAUSCH AND LOMB: PRODUCT PORTFOLIO
  • TABLE 125. BAUSCH AND LOMB: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 126. CARL ZEISS AG: KEY EXECUTIVES
  • TABLE 127. CARL ZEISS AG: COMPANY SNAPSHOT
  • TABLE 128. CARL ZEISS AG: OPERATING SEGMENTS
  • TABLE 129. CARL ZEISS AG: PRODUCT PORTFOLIO
  • TABLE 130. CARL ZEISS AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 131. RAYNER COMPANY: KEY EXECUTIVES
  • TABLE 132. RAYNER COMPANY: COMPANY SNAPSHOT
  • TABLE 133. RAYNER COMPANY: OPERATING SEGMENTS
  • TABLE 134. RAYNER COMPANY: PRODUCT PORTFOLIO
  • TABLE 135. RAYNER COMPANY: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 136. BOHUS BIOTECH AB: KEY EXECUTIVES
  • TABLE 137. BOHUS BIOTECH AB: COMPANY SNAPSHOT
  • TABLE 138. BOHUS BIOTECH AB: OPERATING SEGMENTS
  • TABLE 139. BOHUS BIOTECH AB: PRODUCT PORTFOLIO
  • TABLE 140. BOHUS BIOTECH AB: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 141. COOPERVISION, INC.: KEY EXECUTIVES
  • TABLE 142. COOPERVISION, INC.: COMPANY SNAPSHOT
  • TABLE 143. COOPERVISION, INC.: OPERATING SEGMENTS
  • TABLE 144. COOPERVISION, INC.: PRODUCT PORTFOLIO
  • TABLE 145. COOPERVISION, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 146. LIFECORE BIOMEDICAL, LLC: KEY EXECUTIVES
  • TABLE 147. LIFECORE BIOMEDICAL, LLC: COMPANY SNAPSHOT
  • TABLE 148. LIFECORE BIOMEDICAL, LLC: OPERATING SEGMENTS
  • TABLE 149. LIFECORE BIOMEDICAL, LLC: PRODUCT PORTFOLIO
  • TABLE 150. LIFECORE BIOMEDICAL, LLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 151. AETNA INC.: KEY EXECUTIVES
  • TABLE 152. AETNA INC.: COMPANY SNAPSHOT
  • TABLE 153. AETNA INC.: OPERATING SEGMENTS
  • TABLE 154. AETNA INC.: PRODUCT PORTFOLIO
  • TABLE 155. AETNA INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • LIST OF FIGURES

  • FIGURE 1. GLOBAL APHAKIA MARKET SEGMENTATION
  • FIGURE 2. GLOBAL APHAKIA MARKET
  • FIGURE 3. SEGMENTATION APHAKIA MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN APHAKIA MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALAPHAKIA MARKET
  • FIGURE 11. APHAKIA MARKET SEGMENTATION, BY BY TYPE
  • FIGURE 12. APHAKIA MARKET FOR CONGENITAL APHAKIA, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 13. APHAKIA MARKET FOR SURGICAL APHAKIA, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 14. APHAKIA MARKET FOR ACQUIRED APHAKIA, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 15. APHAKIA MARKET SEGMENTATION, BY BY TREATMENT
  • FIGURE 16. APHAKIA MARKET FOR SPECTACLES, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 17. APHAKIA MARKET FOR CONTACT LENSES, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 18. APHAKIA MARKET FOR INTRAOCULAR LENS IMPLANTATION, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 19. APHAKIA MARKET FOR REFRACTIVE SURGERY, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 20. APHAKIA MARKET SEGMENTATION, BY BY END USER
  • FIGURE 21. APHAKIA MARKET FOR HOSPITALS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 22. APHAKIA MARKET FOR OPHTHALMIC CLINICS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 23. APHAKIA MARKET FOR OTHERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 24. TOP WINNING STRATEGIES, BY YEAR, 2022-2024*
  • FIGURE 25. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2022-2024*
  • FIGURE 26. TOP WINNING STRATEGIES, BY COMPANY, 2022-2024*
  • FIGURE 27. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 28. COMPETITIVE DASHBOARD
  • FIGURE 29. COMPETITIVE HEATMAP: APHAKIA MARKET
  • FIGURE 30. TOP PLAYER POSITIONING, 2024
  • FIGURE 31. JOHNSON AND JOHNSON: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 32. JOHNSON AND JOHNSON: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 33. JOHNSON AND JOHNSON: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 34. OPHTEC BV: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 35. OPHTEC BV: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 36. OPHTEC BV: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 37. ALCON LABORATORIES, INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 38. ALCON LABORATORIES, INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 39. ALCON LABORATORIES, INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 40. BAUSCH AND LOMB: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 41. BAUSCH AND LOMB: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 42. BAUSCH AND LOMB: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 43. CARL ZEISS AG: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 44. CARL ZEISS AG: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 45. CARL ZEISS AG: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 46. RAYNER COMPANY: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 47. RAYNER COMPANY: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 48. RAYNER COMPANY: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 49. BOHUS BIOTECH AB: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 50. BOHUS BIOTECH AB: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 51. BOHUS BIOTECH AB: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 52. COOPERVISION, INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 53. COOPERVISION, INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 54. COOPERVISION, INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 55. LIFECORE BIOMEDICAL, LLC: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 56. LIFECORE BIOMEDICAL, LLC: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 57. LIFECORE BIOMEDICAL, LLC: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 58. AETNA INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 59. AETNA INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 60. AETNA INC.: REVENUE SHARE, BY REGION, 2024 (%)

Purchase Full Report of
Aphakia Market

PURCHASE OPTIONS



* Taxes/Fees, If applicable will be added during checkout. All prices in USD.

Have a question ?

Need to add more ?

Avail up to 30% discount on subscription plans on


Avenue